Prednisolone in Duchenne muscular dystrophy

Area of Science:

• Neurology
• Pediatrics
• Genetics

Background:

• Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration.
• Current treatments aim to manage symptoms and slow disease progression.
• The efficacy of corticosteroids like prednisolone in altering the natural course of DMD requires further investigation.

Purpose of the Study:

• To evaluate the effect of prednisolone on Duchenne muscular dystrophy.
• To assess the impact of prednisolone on muscle strength, functional tests, and functional grades in DMD patients.

Main Methods:

• A randomized controlled study involving 19 Duchenne muscular dystrophy patients.
• The study group (10 patients) received prednisolone (0.75 mg/kg) for six months.
• The control group (8 patients) received vitamin supplementation for six months. Patient outcomes were assessed using muscle strength, timed function tests, and functional grades (pelvic and pectoral).

Main Results:

• Prednisolone treatment led to significant improvements in almost all assessed parameters (P < 0.05).
• Improvements were observed in average muscle strength, timed function tests, and functional grades.
• The study group demonstrated notable gains compared to the control group.

Conclusions:

• Prednisolone is an effective treatment for improving muscle strength and function in Duchenne muscular dystrophy patients.
• The findings suggest that prednisolone can positively modify the natural disease progression of DMD.
• Further research is warranted to confirm long-term efficacy and optimal dosing.